(Q33999757)

English

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (English)

1 reference

Europe PubMed Central

30 July 2017

0 references

0 references

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

10

object named as

M Laakso

1 reference

Europe PubMed Central

30 July 2017

Markolf Hanefeld

8

object named as

M Hanefeld

1 reference

Europe PubMed Central

30 July 2017

1 reference

ORCID Public Data File 2021

14

object named as

R R Holman

1 reference

Europe PubMed Central

30 July 2017

author name string

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators

1

1 reference

Europe PubMed Central

30 July 2017

H C Gerstein

2

1 reference

Europe PubMed Central

30 July 2017

S Yusuf

3

1 reference

Europe PubMed Central

30 July 2017

J Bosch

4

1 reference

Europe PubMed Central

30 July 2017

J Pogue

5

1 reference

Europe PubMed Central

30 July 2017

P Sheridan

6

1 reference

Europe PubMed Central

30 July 2017

N Dinccag

7

1 reference

Europe PubMed Central

30 July 2017

B Hoogwerf

9

1 reference

Europe PubMed Central

30 July 2017

V Mohan

11

1 reference

Europe PubMed Central

30 July 2017

J Shaw

12

1 reference

Europe PubMed Central

30 July 2017

B Zinman

13

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

1 September 2006

1 reference

Europe PubMed Central

30 July 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

30 July 2017

368

1 reference

Europe PubMed Central

30 July 2017

1096-1105

1 reference

Europe PubMed Central

30 July 2017

9541

1 reference

Europe PubMed Central

30 July 2017

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Worst-rank score analysis with informatively missing observations in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Follow-up report on the diagnosis of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fat in the liver and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

TZDs and diabetes: testing the waters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969420-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(06)69420-8

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33999757&oldid=1766341067"